|Ms. Kristi Jones R.Ph.||CEO, Pres & Director||680,44k||N/A||1963|
|Dr. Mathias Oelke Ph.D.||Chief Scientific Officer||621,26k||N/A||1969|
|Mr. John Trainer M.B.A.||Consultant||546,13k||N/A||1974|
|Dr. Jerome Bernard Zeldis M.D., Ph.D.||Consultant||618,2k||N/A||1950|
|Mr. Timothy Stover||VP, Corp. Controller and Principal Financial & Accounting Officer||N/A||N/A||N/A|
|Mr. Karen Haslbeck||Head of HR||N/A||N/A||N/A|
|Dr. Daniel P. Bednarik||Sr. VP of Molecular Engineering & Protein Design||N/A||N/A||N/A|
|Dr. Robert Douglas Knight M.D.||Chief Medical Officer||N/A||N/A||1951|
|Mr. Chad Rubin||Sr. VP of Corp. Affairs||N/A||N/A||N/A|
|Dr. Jack A. Ragheb M.D., Ph.D.||Sr. VP of Translational Science||N/A||N/A||N/A|
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
NexImmune, Inc.s ISS Governance QualityScore, Stand 1. September 2023, lautet 10. Die grundlegenden Scores sind Audit: 9, Vorstand: 8, Shareholderrechte: 8, Kompensation: 10.